• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Who We Are

The International Alliance of ALS/MND Associations was founded in 1992. Today, we bring together almost 80 member organizations across the globe, united by a single purpose: driving global collaboration toward a world free of ALS/MND.

Everything we do is centred around the fundamental rights of people affected by ALS/MND — the belief that where you live should not determine the quality of care, support, and respect you receive.

We work alongside our members to raise awareness, coordinate research, advocate for equitable access to care and therapies, and ensure that under-represented communities are not left behind. Our global reach means that knowledge, tools, and best practices developed anywhere in the world can benefit people everywhere.

Our Vision: A world free of ALS/MND

Our Aspiration: To drive global collaboration

Our Reach: We work globally, serving the entire ALS/MND community — people living with the disease, caregivers, clinicians, researchers, and the organizations that support them.

Our Purpose: Everything we do is oriented around one purpose: accelerating progress on the Fundamental Rights of people affected by ALS/MND, everywhere in the world.

Our Strategic Priorities

The Alliance’s 2026–2028 Strategy sets out six priorities that will guide our work over the coming years.

  • Bring focus to quality of life for PALS and their community: We advocate more effectively to improve outcomes by understanding what people living with ALS/MND (PALS) and their community identify as important.
  • Include under-represented communities: By working alongside under-represented communities, we ensure meaningful inclusion across the globe so geography does not dictate destiny.
  • Increase awareness of ALS/MND: By raising awareness of ALS/MND and the Alliance, we strengthen our advocacy efforts at the global level, which supports our members at the local level.
  • Facilitate research coordination: By bringing people together and facilitating research coordination across the globe, we deepen our understanding of ALS/MND and accelerate research.
  • Leverage collective capacity: By coordinating with our members and partnering in strategic international collaborations, we leverage collective knowledge and resources — positioning the Alliance as a trusted source of evidence-based information, best practices, and tools.
  • Grow the community: By identifying and inviting ALS/MND organizations not yet part of the Alliance, and by supporting the creation and development of new organizations, we expand the community working toward a world free of ALS/MND.

Alliance Strategy 2026-2028: Our three-year roadmap for driving global collaboration toward a world free of ALS/MND.

Annual Report 2024-2025: A review of the Alliance’s work and impact over the past year.

Primary Sidebar

About

  • Who We Are
  • Board of Trustees
  • Councils, Forums & Committees
    • PALS and CALS Advisory Council
    • Scientific Advisory Council
    • Advocacy and Public Policy Forum
    • Research Directors Forum
    • Governance Committee
    • Finance Committee
  • Staff
  • History
  • Newsletter Archive
    • Newsletters
    • Meetings
  • Awards

  • Danny Reviers, Belgium

    Danny Reviers, Belgium

  • Susan Keldani, USA

    Susan Keldani, USA

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Animesh Kumar, India

    Animesh Kumar, India

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

  • Claudia Cominetti, Italy

    Claudia Cominetti, Italy

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Mauril Bélanger, Canada

    Mauril Bélanger, Canada

  • Michel Perrozzo, France

    Michel Perrozzo, France

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Ana Lilia Rodriguez, Mexico

    Ana Lilia Rodriguez, Mexico

  • Anna Barrow, UK

    Anna Barrow, UK

  • Alfredo Santos, Colombia

    Alfredo Santos, Colombia

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Hanne Stenmose, Denmark

    Hanne Stenmose, Denmark

  • Andrea Zicchieri, Italy

    Andrea Zicchieri, Italy
    AndreaZicchieri_conSLAncioItaly

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Lee Millard, England

    Lee Millard, England

  • Christian Bär, Germany

    Christian Bär, Germany

  • Ali Var, Turkey

    Ali Var, Turkey

  • Rosie Riley, USA

    Rosie Riley, USA

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Fayette Underwood, USA

    Fayette Underwood, USA

  • Mirca Bersani, Italy

    Mirca Bersani, Italy
    MircaBersani

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Alex, Argentina

    Alex, Argentina

  • Kirsten Harley, Australia

    Kirsten Harley, Australia

  • Chih Ching Darren Wong, Malaysia

    Chih Ching Darren Wong, Malaysia

  • Hollister

    Hollister
    hollister

  • Liz Ogg, Scotland

    Liz Ogg, Scotland

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Jon Newsome, USA

    Jon Newsome, USA

  • Francisco Perez Palop, Spain

    Francisco Perez Palop, Spain

  • Guido De Mets, Belgium

    Guido De Mets, Belgium

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Wendy Hendrickson, USA

    Wendy Hendrickson, USA

  • Den Haag, Netherlands

    Den Haag, Netherlands

  • Alejandro Aquino, Argentina

    Alejandro Aquino, Argentina

  • Bayley, Australia

    Bayley, Australia

  • Debbie Craghill, USA

    Debbie Craghill, USA

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • Danny Reviers, Belgium

    Danny Reviers, Belgium
    DannyReviers

  • Dan Doctoroff, USA

    Dan Doctoroff, USA

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login